Gufic Biosciences Limited
Momentum (98/100) does the heavy lifting; valuation (22/100) is the drag.
ExpensiveGufic Biosciences Limited earns a Buy from StocksWizard, with a blended score of 60/100. We put fair value near ₹297.32; at ₹389.85 that leaves roughly 24% downside, so the stock screens overvalued by 24%. On 59.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 4% below its 52-week high of ₹407.05 and 43% above the low of ₹273.5. Financial health scores 82/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. It clears 6 of 13 investability checks, with durability 51, valuation 34 and momentum 98 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹237.86.
1-year price
EOD · 2026-07-3152-week range
-4.23% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy60Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 10.1%
- Fail: Low debt (D/E < 0.5): 0.61x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 23%
- Pass: Earnings growing: 183%
- Fail: Net margin ≥ 10%: 6.8%
- Pass: Current ratio > 1.5: 1.55
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.28
- Fail: Piotroski ≥ 7: 6/9
Shareholding
- Promoter77.5%
- Institutions3.3%
- Public & other19.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Financially solid — Altman Z 4.28.
Opportunities
- Earnings growing (183% YoY).
- Revenue growing (23% YoY).
Bear case
Threats
- Trades ~24% above our estimated fair value.
About Gufic Biosciences Limited
Gufic Biosciences manufactures and markets active pharmaceutical ingredients, generic pharmaceuticals, and related services across India, Africa, Asia, Europe, Australia, North America, and South America. The company produces APIs and bulk drugs including antifungals, anesthetics, immunosuppressants, angiotensin receptor blockers, and antifungal intermediates, as well as lyophilized injections for antibiotics, antifungals, and cardiac medications.
Gufic Biosciences Limited — frequently asked questions
Is Gufic Biosciences Limited a buy, hold or sell?
StocksWizard currently rates Gufic Biosciences Limited (GUFICBIO) a Buy, based on a blended score of 60/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Gufic Biosciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Gufic Biosciences Limited's fair value at about ₹297.32, versus a current price of ₹389.85 — roughly 24% downside. On that basis the stock looks overvalued by 24%.
Is Gufic Biosciences Limited financially healthy?
Gufic Biosciences Limited scores 82/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Gufic Biosciences Limited's share price performed?
Gufic Biosciences Limited is up 36% over three months, and last traded at ₹389.85. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.